Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $19.00 Average Price Target from Analysts

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $19.00.

ENTA has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and issued a $27.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, August 6th. JPMorgan Chase & Co. lowered their target price on Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating on the stock in a report on Tuesday, August 6th. Finally, Evercore ISI upgraded Enanta Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, August 6th.

Insider Transactions at Enanta Pharmaceuticals

In other news, insider Scott T. Rottinghaus sold 5,375 shares of the firm’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $17.08, for a total transaction of $91,805.00. Following the sale, the insider now owns 21,717 shares in the company, valued at $370,926.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Scott T. Rottinghaus sold 4,299 shares of the stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $15.07, for a total value of $64,785.93. Following the transaction, the insider now directly owns 23,988 shares of the company’s stock, valued at approximately $361,499.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Scott T. Rottinghaus sold 5,375 shares of the stock in a transaction on Monday, July 15th. The stock was sold at an average price of $17.08, for a total value of $91,805.00. Following the completion of the transaction, the insider now directly owns 21,717 shares in the company, valued at $370,926.36. The disclosure for this sale can be found here. Insiders own 13.64% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Farallon Capital Management LLC raised its position in shares of Enanta Pharmaceuticals by 3.5% in the 1st quarter. Farallon Capital Management LLC now owns 2,095,000 shares of the biotechnology company’s stock worth $36,579,000 after buying an additional 70,000 shares during the period. Vanguard Group Inc. raised its position in shares of Enanta Pharmaceuticals by 7.5% in the 1st quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock worth $33,664,000 after buying an additional 134,292 shares during the period. Acadian Asset Management LLC raised its position in Enanta Pharmaceuticals by 1.3% in the first quarter. Acadian Asset Management LLC now owns 853,896 shares of the biotechnology company’s stock valued at $14,906,000 after purchasing an additional 10,952 shares during the period. Bank of New York Mellon Corp raised its position in Enanta Pharmaceuticals by 13.3% in the second quarter. Bank of New York Mellon Corp now owns 73,841 shares of the biotechnology company’s stock valued at $958,000 after purchasing an additional 8,645 shares during the period. Finally, Cubist Systematic Strategies LLC raised its position in Enanta Pharmaceuticals by 65.8% in the second quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company’s stock valued at $588,000 after purchasing an additional 18,003 shares during the period. 94.99% of the stock is owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Price Performance

ENTA opened at $11.30 on Tuesday. The stock has a market cap of $239.32 million, a P/E ratio of -1.81 and a beta of 0.59. The stock’s 50 day simple moving average is $13.28 and its 200 day simple moving average is $13.64. Enanta Pharmaceuticals has a 1-year low of $8.08 and a 1-year high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.43) by $0.36. The business had revenue of $17.97 million for the quarter, compared to analysts’ expectations of $17.44 million. Enanta Pharmaceuticals had a negative return on equity of 63.75% and a negative net margin of 160.27%. The company’s revenue was down 4.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.27) EPS. Research analysts expect that Enanta Pharmaceuticals will post -5.3 EPS for the current fiscal year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.